|
|
|
| Meta-analysis of protective efficacy of oral pentavalent human-bovine reassortant rotavirus live-attenuated vaccine |
| HU Yu，CHEN Ya-ping，LIANG Hui，WANG Ying
|
| Department of Immunization Program，Zhejiang Provincial Center for Disease Control and Prevention，Hangzhou，Zhejiang 310051，China |
|
|
|
|
Abstract Objective To evaluate the protective efficacy（VE）of oral pentavalent human-bovine reassortant rotavirus live-attenuated vaccine（PRV）. Methods We searched China Biology Medicine disc，China National Knowledge Infrastructure，Wanfang Database，National Center for Biotechnology Information and Cochrane Library about VE of PRV. Pooled estimates of odds ratio（OR）or relative risk（RR）of the incidence rates of rotavirus gastroenteritis and the vaccine efficacy（VE）were calculated according to the socio-economic development level and match of vaccine strains with pandemic strains，specifically. Results Five studies were included. In the highly developed countries，VE was 94%（95%CI：84%-98%）against homotypic strains，82%（95%CI：70%-89%）against partly heterotypic strains，82%（95%CI：70%-89%）against single-antigen vaccine type strains，and 75% （95%CI：47%-88%）against single-antigen non-vaccine type strains. In the middle developed countries，VE was 37%（95%CI：10%-56%）against partly heterotypic strains，71%（95%CI：60%-78%）against single-antigen vaccine type strains，and 76%（95%CI：61%-85%）against single-antigen non-vaccine type strains. Conclusion PRV can reduce the incidence of rotavirus gastroenteritis. The VE of PRV is related to the socio-economic development level and match of vaccine strains with pandemic strains.
|
|
Published: 26 September 2018
|
|
|
|
|
|
[1] BURNETT E，JONESTELLER C L，TATE J E，et al. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea[J] . J Infect Dis，2017，215（11）：1666-1672.
[2] KULKARNI P S，DESAI S，TEWARI T，et al. A randomized Phase Ⅲclinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants[J] . Vaccine，2017，35（45）：6228-6237.
[3] TATE J E，PATEL M M，CORTESE M M，et al. Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality[J] . Expert Rev Vaccines，2012，11（2）：211-220.
[4] B??YAI K，L??ZL??B，DUQUE J，et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era：insights for understanding the impact of rotavirus vaccination programs[J] . Vaccine，2012，30（Suppl 1）：A122-A130.
[5] GUYATT G H，OXMAN A D，VIST G E，et al. GRADE：an emerging consensus on rating quality of evidence and strength of recommendations[J] . BMJ，2008，336（7650）：924-926.
[6] CORTESE M M，IMMERGLUCK L C，HELD M，et al. Effectiveness of monovalent and pentavalent rotavirus vaccine[J] . Pediatrics，2013，132（1）：e25-e33.
[7] PAYNE D C，BOOM J A，STAAT M A，et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age，2009-2011[J] . Clin Infect Dis，2013，57（1）：13-20.
[8] STAAT M A，PAYNE D C，DONAUER S，et al. Effectiveness of pentavalent rotavirus vaccine against severe disease[J] . Pediatrics，2011，128（2）：e267-e275.
[9] MAST T C，KHAWAJA S，ESPINOZA F，et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua[J] . Pediatr Infect Dis J，2011，30（11）：e209- e215.
[10] PATEL M. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua[J] . Jama，2009，301（21）：2243.
[11] VESIKARI T，ITZLER R，KARVONEN A，et al. RotaTeq，a pentavalent rotavirus vaccine：efficacy and safety among infants in Europe[J] . Vaccine，2009，28（2）：345-351.
[12] CLARK H F，BERNSTEIN D I，DENNEHY P H，et al. Safety，efficacy，and immunogenicity of a live，quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants[J] . J Pediatr，2004， 144（2）：184-190.
[13] ARAUJO E C，CLEMENS S A，OLIVEIRA C S，et al. Safety，immunogenicity，and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants[J] . J Pediatr （Rio J），2007，83（3）：217-224.
[14] WANG F T，MAST T C，GLASS R J，et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States[J] . Pediatrics，2010，125（2）：e208-e213.
[15] GOVEIA M G，DINUBILE M J，DALLAS M J，et al. Efficacy of pentavalent human-bovine（WC3）reassortant rotavirus vaccine based on breastfeeding frequency[J] . Pediatr Infect Dis J，2008， 27（7）：656-658.
[16] 司璐，魏至栋. 轮状病毒疫苗的研发进展[J] . 中国生物制品学杂志，2018，31（2）：210-214.
[17] 任江萍，陈恩富. 轮状病毒流行病学与疫苗研究进展[J] . 浙江预防医学，2015，27（8）：801-804.
[18] 卢丽娟，钟华清，苏犁云，等. 2008至2011年上海单中心住院腹泻儿童轮状病毒基因型别流行特征[J] . 中国循证儿科杂志，2013，8（2）：98-104.
[19] G??EZ M M，DE MENDON?A M C，VOLOT?O EDE M，et al. Rotavirus A genotype P[4] G2：genetic diversity and reassortment events among strains circulating in Brazil between 2005 and 2009[J] . J Med Virol，2011，83（6）：1093-1106.
[20] KIRKWOOD C D，BONIFACE K，BISHOP R F，et al. Australian Rotavirus Surveillance Program annual report，2008/2009[J] . Commun Dis Intell Q Rep，2009，33（4）：382-388.
[21] CORTES J E，CURNS A T，TATE J E，et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children[J] . The New England journal of medicine，2011，365（12）：1108-1117.
[22] GASTA?ADUY P A，SáNCHEZ-URIBE E，ESPARZA-AGUILAR M，et al. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico[J] . Pediatrics，2013，131（4）：e1115-e1120. |
|
|
|
